SEARCH · Search PubMed

Results for “Oncogene”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

SourceResearch connectionFrom yearThrough year

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 73 records · Page 4Linked to original sources

PubMedDate not supplied

[Oncogene-directed mutagenesis in vivo. Polyalkylating derivatives of short single-stranded polynucleotides, complementary E1-adeno-oncogene, in the normalization of adenovirus-transformed rodent cell lines].

Polyalkylating derivatives of single-stranded polynucleotides (30-200-mers) complementary to the long E1 oncogene sequences of simian adenovirus SA7 cause inherited normalization of SH2 and G11 cells transformed with adenovirus SA7; certain deletions in the integrated proviral E1A oncogene were observed in several cases during this process. The transformed cells are indifferent to reagents noncomplementary to the E1 region. Thus polyalkylating derivatives of single-stranded 30-200-mers act as addressed mutagenes which react in a specific way with the integrated complementary DNA sequences of E1 oncogene in transformed rodent cells and realize oncogene-directed mutagenesis in vivo. During this treatment temporary normalized cells reverting to the initial transformed phenotype are also produced.

Adenoviruses, Simian↗

PubMedDate not supplied

[Retroviral oncogenes and their cellular proto-oncogenes].

Recent data on the genome structure of transforming retroviruses and their cellular counterparts has been reviewed. Retroviruses are divided in several groups according to their oncogenic potential. Comparison of oncogenes and their protein products for most abundant transforming viruses are presented. Probable mechanisms of capture of cellular proto-oncogenes by retroviruses and the hypothesis of existence of endogenous transforming viruses are discussed. General features of cellular proto-oncogenes and possible ways of their activation resulting in neoplastic transformation are discussed. Some unresolved problems of retroviral carcinogenesis, in particular, the problem of existence of unidentified "X"-genes in retroviral genomes and involvement of constitutional viral genes in carcinogenesis are mentioned.

Amino Acid Sequence↗

PubMed1984

[New knowledge on the molecular mechanism of activation of oncogenes and effect of oncogene DNA on protein synthesis].

It is reported on recent recognitions in the activation of cellular oncogens by carcinogens, by exchange (translocation) of genes within various chromosomes as well as by infection by the proviruses DNA of retroviruses. Cellular oncogens can be activated by a mutation already by the exchange of a base in a desoxyribonucleotide. Mutations develop under the influence of carcinogens. The protein changed in a amino acid portion accepts transforming properties. The Epstein-Barr virus furthers the increase of the number of B-lymphocytes. In this case may take place a translocation of the oncogen c-myc of the chromosome 8 into the region of the gen-recombination for the formation of the polypeptide chains of the immunoglobulins in the chromosomes 2, 14, and 22, respectively: in this area is an acceleration factor for the transcription. Cellular oncogens may be activated by retroviruses also by the long terminal repetitive parts of the proviruses. Papilloma viruses relatively frequently appear in the carcinomas of the cervix.

Animals↗

PubMed1990

The c-ets-1 proto-oncogene has oncogenic activity and is positively autoregulated.

The proto-oncogene ets-1 is a member of the ets family of genes that share homology with the viral oncogene, v-ets, of the avian leukemia virus E26. By using expression vectors, we demonstrate that the ets-1 gene transforms NIH3T3 cells and the ets-1 transfected cells form colonies in soft agar and induce tumors in nude mice. We have also determined that the ets-1 protein contains homology with the helix-loop-helix motif of the HLH family proteins, but lacks the basic domain upstream of helix I. Transfection of the NIH3T3 cells with ets-1 vectors results in the activation of the endogenous ets-1 gene. Using hybridization probes that can distinguish between transcripts from endogenous and exogenous templates, we show that the endogenous ets-1 gene is activated by the expression of the transfected exogenous ets-1. In contrast, the expression of transfected ets-2 has no effect on the endogenous ets-1 gene expression. The results indicate that the ets-1 proto-oncogene is positively autoregulated by its product.

Amino Acid Sequence↗

PubMed1987

Potential oncogenic hazards posed by oncogene encoded proteins.

The theoretical risk from oncogene encoded proteins is limited to growth factors, which may be secreted by cells in which biologically derived products might be manufactured. Because these peptides do not replicate, their effect is finite. In addition, their effects are reversible. Growth factors do not ordinarily appear to be oncogenic. Even under circumstances in which they contribute to oncogenicity, repeated administration of high concentrations of growth factors (several micrograms per kilogram) would appear to be required for them to serve as co-factors in the carcinogenic process, and the resulting tumors appear to remain dependent upon the continued presence of the growth factor for continued tumor growth.

Animals↗

PubMed1993

Amplification of c-MYC oncogene and point mutation of N-RAS oncogene point mutation in acute myelocytic leukemias with double minute chromosomes.

Two patients with acute myelocytic leukemia (AML) showing double minute (dmin) chromosomes were analysed to identify oncogene activation. Cytogenetic analysis showed 1-53 dmin chromosomes with the normal karyotype in the first patient and 1-84 dmin chromosomes with complex chromosome aberrations. Analysis of DNA from two patients revealed five- to tenfold amplification of c-MYC oncogene in the leukemic cells. The other sixteen oncogenes studied showed no increase in the gene content. Furthermore, a transforming gene, N-RAS was detected in the first patient by nude mouse tumorigenicity assay (in vivo selection assay). These results suggest that the amplification of c-MYC gene is common in dmin-positive AML patients and co-ordination of c-MYC and N-RAS oncogene might also play a significant role in the pathogenesis of some AML patients.

Aged↗

PubMed1998

[Effect of ionizing radiation on the mitotic cycle of rat embryonal cells, immortalized by oncogene E1A and transformed by oncogenes E1A and c-Ha-ras].

A comparative study of recovery of mitotic cycle in gamma-irradiated rat embryo fibroblast cells (intact, immortalized with oncogene E1A and transformed with two oncogens-E1A and c-Ha-Ras) was made to show eventually no difference in response to 5 Gy irradiation of intact and immortalized cells, and, on the other side, to demonstrate a great difference in response of immortalized and transformed cells. Cells transformed with the two oncogens E1A and c-Ha-Ras appeared to be much more resistant to ionizing radiation than intact cells and cells immortalized with one oncogene E1A. These data allow to suggest protein p53 tumor-suppressor functioning in transformed cells, but not in intact and immortalized cells.

Adenovirus E1A Proteins↗

PubMed1990

Oncogenes and anti-oncogenes.

The study of oncogenes offers insights into many steps in signal transduction. Rapid progress is possible because of the combination of biochemistry and genetics--unique in vertebrate cell biology--the availability of specific clones and antibodies, sequence information, dominant mutants, and biochemical assays of function. The wealth of detail on oncogenes and proto-oncogenes continues to increase dramatically. Hopefully, in the next year or two some of the gaps will be filled in and all the steps along at least one pathway from the cell membrane to the nucleus will be understood.

Animals↗

PubMed2001

Oncogenic potential of mouse translation elongation factor-1 delta, a novel cadmium-responsive proto-oncogene.

The molecular mechanisms potentially responsible for cadmium-induced cell transformation and tumorigenesis were investigated using Balb/c-3T3 cells transformed with cadmium chloride. Differential display analysis of gene expression revealed consistent and reproducible overexpression of a transcript in the transformed cells compared with the nontransformed cells. The full-length cDNA corresponding to the differentially expressed transcript was cloned and was identified as mouse translation elongation factor-1 delta subunit (TEF-1 delta; GenBank accession number ). Nucleotide sequence analysis of TEF-1 delta cDNA revealed an open reading frame encoding the predicted protein of 281 amino acids and exhibited significant conservation with the corresponding protein of human, Xenopus laevis, and Artemia. The presence of a leucine zipper motif, characteristic of translation elongation factor-1 delta, was also found in the mouse TEF-1 delta. A 31-kDa protein was detected in eukaryotic cells transfected with an expression vector containing the TEF-1 delta cDNA. Overexpression of the TEF-1 delta protein by transfection was oncogenic in NIH3T3 cells as evidenced by the appearance of transformed foci exhibiting anchorage-independent growth and the potential to grow as tumors in nude mice. Blocking the translation of TEF-1 delta with antisense TEF-1 delta mRNA resulted in a significant reversal of the oncogenic potential of cadmium-transformed Balb/c-3T3 cells as evidenced from suppression in anchorage-independent growth and tumorigenesis in nude mice. Our findings demonstrate, for the first time, that the cell transformation and tumorigenesis induced by cadmium are due, at least in part, to the overexpression of TEF-1 delta, a novel cadmium-responsive proto-oncogene.

3T3 Cells↗

PubMed2001

Human papilloma virus 16 E7 oncogene does not cooperate with RET/PTC 3 oncogene in the neoplastic transformation of thyroid cells in transgenic mice.

We have previously reported that the thyroid-targeted expression of the RET/PTC3 oncogene (Tg-RET/PTC3) in transgenic mice induces follicular hyperplasia with papillary architecture, resulting in a modest increase of the thyroid gland volume, followed by the appearance of papillary carcinomas in approximately 1-year-old animals. In order to analyze the genetic alterations that may cooperate with RET/PTC3 in the development or progression of thyroid tumors, we interbred Tg-RET/PTC3 mice with Tg-E7 transgenic mice, which express the E7 oncogene of the human papilloma virus 16 in thyroid cells. Tg-E7 mice develop large colloid goiters with small papillae and well-differentiated thyroid carcinomas in older animals. Here we show that thyroid lesions in Tg-RET/PTC3-Tg-E7 double transgenics were morphologically different from those occurring in Tg-RET/PTC3 mice, while they were virtually indistinguishable from those occurring in Tg-E7 mice. In addition, the coexpression of RET/PTC3 and E7 oncogenes neither enhanced the malignant phenotype nor reduced the latency period of thyroid lesions with respect to parental transgenic lines. We conclude that the coexpression of RET/PTC3 and E7 lacks any cooperative effect in the neoplastic transformation of thyroid cells and that the E7-induced thyroid phenotype is dominant with respect to the RET/PTC3 one.

Age Factors↗

PubMed1992

EGF receptor activity and mitogenic response of Balb/3T3 cells expressing Ras and Myc oncogenes. EGF receptor activity in oncogene transformed cells.

EGF receptors are found on the surface of most cells, usually with high and low binding affinities. To investigate functional relationships between EGF (EGF-like growth factors) and oncogenes we have characterized the expression of the epidermal growth factor receptor (EGFr) in H-Ras, v-Myc, and H-Ras-v-Myc transformed Balb/3T3 cells. H-Ras cells show a marked decrease in the number of EGFr molecules per cell compared to parental cells. v-Myc and H-Ras-v-Myc transformed cells express an intermediate level of receptors. The majority of the EGF receptors on the parental and oncogene transformed cells bind EGF with low affinity and this low affinity receptor is down-regulated by oncogene transformation. v-Myc expression, in the H-Ras-v-Myc transformed cells, abrogates the receptor down-regulation seen with H-Ras transformation. The mechanism of abrogation is not a result of a change in the p21-Ras concentration in the H-Ras-v-Myc transformed cells. In addition, the mitogenic response to EGF was examined. H-Ras and H-Ras-v-Myc transformed cells do not respond to EGF mitogenically. In contrast, EGF stimulates DNA synthesis in parental cells and v-Myc transfected cells; this result suggests that growth promoting signals from the EGF receptor may not be required in H-Ras transformed cells.

3T3 Cells↗

PubMed1989

Activation of the ret-II oncogene without a sequence encoding a transmembrane domain and transforming activity of two ret-II oncogene products differing in carboxy-termini due to alternative splicing.

We previously reported the cloning of a transforming gene, ret-II, which contains the proto-ret kinase domain. In the present study ret-II cDNAs were cloned from a transformant and analyzed. The restriction map and nucleotide sequence indicated that the sequence upstream of the proto-ret kinase domain was replaced by another sequence, which encoded a fusion protein composed of 899 amino acids. This non-proto-ret sequence differed from that of the ret previously reported and had no hydrophobic amino acid stretch for a transmembrane domain. Furthermore, we obtained two kinds of ret-II cDNAs differing in their 3' regions and found that the differences were generated by alternative splicing. From these cDNAs, two types of oncogene products differing in their carboxy-terminal amino acid residues were predicted. The two products exhibited similar transforming activity in NIH3T3 cells. These data indicate that activation of proto-ret can occur as a result of replacement of the extra-cellular and transmembrane domains with the hydrophilic sequence. In addition, differences in the carboxy-terminal amino acid residues in the two types of ret-II oncogene products have no influence on the transforming activity of the ret-II oncogene.

Amino Acid Sequence↗

PubMed1995

[Identification of oncogenes and anti-oncogenes].

In spite of early observations indicating an association of cancer with genomic alterations, the precise knowledge of the causal mutations was only initiated since the last 20 years when the techniques of molecular genetics were applied to observations obtained by investigators working in the field of retrovirology, cell biology, cytogenetics and human genetics. A large number of genes which are recurrently altered in defined tumor types has been identified. Schematically it is possible to distinguish dominant mutations which lead to the oncogenic conversion of proto-oncogenes and recessive mutations of antioncogenes which require for phenotypic expression the inactivation of the second allele. Activation of protooncogenes and inactivation of antioncogenes cooperate within the same cells to the determination of the tumor phenotype. Inherited alterations causing major predisposition to tumor development involve most frequently antioncogenes. Most proto-oncogenes and major tumor susceptibility genes are now known. However, we have a poor understanding of the pathologic mechanism triggered by their mutations.

Chromosome Deletion↗

PubMed1994

Oncogenic activation of human R-ras by point mutations analogous to those of prototype H-ras oncogenes.

R-ras, K-rev-1/rap and TC21, are more closely related to prototype H-ras than any other known members of the ras superfamily. We recently isolated a mutationally activated TC21 oncogene from a human ovarian carcinoma cell line. Based upon these observations, we sought to re-examine the transforming potential of R-ras, which was reported earlier to lack transforming capacity. Mutations were introduced into the R-ras gene at codons 38 or 87, analogous to positions 12 and 61, respectively, responsible for H-ras oncogene activation. While both mutations resulted in acquisition of R-ras transforming capacity for NIH3T3 cells the position 61 was shown to be more active. Transfectants expressing either R-ras mutant formed colonies in soft agar and were tumorigenic in vivo. As has been reported for H-ras, R-ras cooperated with c-raf-1 in inducing transformation of NIH3T3 cells. These results imply interactions in R-ras and c-raf-1 signaling pathways. We observed R-ras transcripts of 4.6 and 1.2 kb ubiquitously expressed in each of a variety of tissues examined. All these findings raise the possibility that R-ras, like prototype ras genes, may be mutationally activated as an oncogene in some human malignancies.

3T3 Cells↗

PubMed1990

The v-rel oncogene product is complexed with cellular proteins including its proto-oncogene product and heat shock protein 70.

The oncogene product, pp59v-rel, of avian reticuloendotheliosis virus (REV-T) is complexed in the cytosol of REV-T transformed lymphoid cells with cellular proteins. Monoclonal antibodies and antisera directed against different regions of pp59v-rel coimmunoprecipitate five cellular proteins (p124, p115, p75, p70, and p40) in addition to pp59v-rel. Cellular proteins with the same apparent molecular mass also copurify with pp59v-rel during sequential Sephacryl S200 and immunoaffinity chromatography. Antisera directed against the most abundant cellular protein in the complex, pp40, coimmunoprecipitate pp59v-rel and several cellular proteins with the same apparent molecular mass. The 75-kDa protein in the pp59v-rel complex is the product of c-rel proto-oncogene and is weakly phosphorylated. In MSB-1 cells this protein is not detectably phosphorylated or associated with cellular proteins. The 70-kDa protein in the pp59v-rel containing cytosolic complex is the constitutive form of avian heat shock protein 70 (HSC70). The p70 protein coimmunoprecipitates and copurifies with pp59v-rel using antisera directed against pp59v-rel and coimmunoprecipitates with antisera specific for pp40. The p70 isolated from immune complexes containing pp59v-rel shares V8 protease fragments with HSC70.

Animals↗

PubMed1997

Oncogenic rearrangements of the ret proto-oncogene in thyroid tumors induced after exposure to ionizing radiation.

A high frequency (approximately 60%) of ret rearrangements in Chernobyl papillary thyroid carcinomas (PTC) has been reported recently. The data suggested that the radiation exposure may be a direct inducer of activating rearrangements in the ret gene. In our study, we have analyzed for the presence of RET/PTC oncogenes using the RT-PCR, XL-PCR, Southern blot and direct sequencing techniques, 39 human thyroid tumors from patients who had received external radiation for benign or malignant conditions. As controls, we studied 39 'spontaneous' tumors. Our results indicate that: 1) the overall frequency of ret rearrangements was 84% in papillary carcinomas (16/19) and 45% (9/20) in follicular adenomas; 2) in contrast with the results obtained in the Chernobyl tumors, the most frequently observed chimeric gene was RET/PTC1; and 3) all the tumors were negative for RET/PTC2. In the 'spontaneous' tumors, only the papillary carcinomas presented a ret rearrangement (15%: 3/20). Our data confirm the crucial role played by the ret proto-oncogene activating rearrangements in the development of radiation-associated thyroid tumors, and show, for the first time, the presence of RET/PTC genes in follicular adenomas appeared after external irradiation.

Adenoma↗

PubMed1989

Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation.

To determine whether the amplification of the proto-neu oncogene (also called c-erbB-2) plays a role in tumorigenicity, we previously generated an NIH 3T3 transfectant (DHFR/G-8) that carried the amplified proto-neu gene. The DHFR/G-8 cells exhibited normal morphology. Their growth curve was similar to that of NIH 3T3 cells but was different from that of the B104-1 cell, and NIH 3T3 transfectant that carries the activated neu oncogene. When injected into nude mice, B104-1 cells produced tumors within 2 weeks, whereas the DHFR/G-8 cells did not produce tumors until 3 months after injection, and the NIH 3T3 cells did not produce any tumors even after 3 months. The tumors produced by the injection of the DHFR/G-8 cells were excised and grown in culture. The cells derived from the tumors were of transformed morphology and highly tumorigenic. The DNAs from the tumor cells were transfected into NIH 3T3 cells. The transfection resulted in foci on the NIH 3T3 monolayer. Southern analysis indicated that the foci derived from the transfection contained the neu gene. Using oligonucleotides as probes, the neu gene in the foci was found to carry a single-point mutation identical to the one previously found in the rat neuroblastoma and glioblastoma induced by the ethylnitrosourea. We conclude that the DNA region encoding the transmembrane domain of neu is a hot spot for converting the proto-neu gene into an activated oncogene and that amplification of the proto-neu gene facilitates mutation of the hot spot.

Animals↗

PubMed1985

Nucleic acid sequence database VI: Retroviral oncogenes and cellular proto-oncogenes.

The databases of the Protein Identification Resource at the National Biomedical Research Foundation (NBRF) contain nucleic acid and protein sequences from 18 retroviral oncogenes (v-onc) and 8 cellular proto-oncogenes (c-onc). Comparison of the sequences between the v-onc and c-onc genes reveals: (i) The c-src, c-abl, c-mos, c-fos, c-ras, c-myb, c-myc, and c-sis genes contain coding regions that are highly conserved in the respective v-onc genes with a small number of base changes. (ii) There are more transitions than transversions. (iii) Some of these base changes are silent mutations and others generate amino acid substitutions in the viral proteins. The causes of these base changes in the coding sequences and the significance to oncogenic transformation of the amino acid substitutions in the viral proteins remain to be determined.

Animals↗